<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819637</url>
  </required_header>
  <id_info>
    <org_study_id>ASRC947</org_study_id>
    <nct_id>NCT00819637</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients</brief_title>
  <official_title>A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the best dose of nebulized arformoterol, a quick
      onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics
      presenting to the the Emergency Department. Also this study will evaluate the side effect and
      safety profile of arformoterol when used in this situation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the
      mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in
      repetitive fashion depending on the resolution of the airways obstruction. Formoterol is a
      long-acting (&gt;12 hours) selective beta2-agonist that has a very rapid onset of
      bronchodilatation (&lt;3 minutes and thus similar to that produced by albuterol). Patients with
      acute bronchospasm could benefit from the prn use of formoterol as they would receive acute
      relief of their symptoms and this would last for a prolonged time period. Additionally
      formoterol has been reported to be 28-109 times as potent as albuterol and safe at doses of
      54ug in healthy subjects and asthmatics. Racemic formoterol structurally has 2 chiral centers
      and thus is composed of 4 enantiomers. The RR form (or arformoterol) is the active
      bronchodilator and it is not clear what the physiologic actions of the other 3 enantiomers
      are. This study is the first to evaluate nebulized arformoterol solution for therapy of acute
      asthmatics presenting to the Emergency Department.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll r/t study design &amp; staffing issues. The trial terminated.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Averaged Mean Percent Change From Baseline FEV1 and PEFR (Percent Predicted and Absolute) After the 3 Doses of Study Drug</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most Effective Dose of Inhalation Arformoterol for Treating Acute Bronchospasm in Asthmatics by Evaluating the Averaged Mean Percent Change From Baseline % Predicted FEV1 After 3 Doses of Study Medication in Each of the 3 Groups</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Treated With Arformoteral in Acute Asthma Exacerbation as a Measure of Safety and Tolerability.</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Peak Change (Liters) and Peak Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Onset of a 15% Improvement in FEV1 for Each Dose (Individual and Cumulative) and Total Dose of Study Medication to Reach This</measure>
    <time_frame>5 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time Required to Achieve a FEV1 and PEFR &gt; 60% Predicted for Each Dose (Individual and Cumulative)</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Responders (Defined as Those Discharged Following Treatment Who Did Not Require Additional Therapy in the ED)</measure>
    <time_frame>5 hours</time_frame>
    <description>The 2 subjects enrolled were both discharged home after study protocol completion, with no further treatment required in the ED setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients in Each Group Requiring Additional Therapies After the First Hour of Study Drug Treatments</measure>
    <time_frame>5 hours</time_frame>
    <description>2 subjects were enrolled. Neither required additional asthma treatment after the 1st hour of study drug teatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All of the Primary and Secondary Endpoints Partitioned by the Presenting PFT in Quartiles and the Presenting S Albuterol Levels in Quartiles</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Arformoterol in This Clinical Setting</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Asthma</condition>
  <arm_group>
    <arm_group_label>Arformoterol 3 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arformoterol 1 dose, placebo 2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levalbuterol 3 doses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arformoterol (RR formoterol)</intervention_name>
    <description>Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.
Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.</description>
    <arm_group_label>Arformoterol 3 doses</arm_group_label>
    <arm_group_label>Arformoterol 1 dose, placebo 2 doses</arm_group_label>
    <other_name>Brovana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.</description>
    <arm_group_label>Arformoterol 1 dose, placebo 2 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levalbuterol</intervention_name>
    <description>Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.</description>
    <arm_group_label>Levalbuterol 3 doses</arm_group_label>
    <other_name>Xopenex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  FEV1 between 20 and 60% predicted after having received 5 mg of albuterol and 0.5 mg
             of atrovent as nebulized standard of care therapy

          -  Male or female between the ages of 18 and 45

          -  Asthma diagnosed by a physician and present for at least 6 months

          -  oxygen saturation greater or equal to 90% on room air

          -  Non smoker or &lt; 10 pack-year history

          -  No other cause for wheezing/sob as determined by the treating physician

        Exclusion Criteria:

          -  Clinical evidence or history of hepatic, renal, cardiovascular, GI, endocrine,
             metabolic or CNS disease which might interfere with the conduct of the study

          -  Acute respiratory failure or other significant pathology of the pulmonary system

          -  Female subjects who are pregnant or lactating

          -  Currently receiving therapy for a psychiatric disorder

          -  Subjects with a known sensitivity to formoterol (racemic or RR) or albuterol (racemic
             or lev)

          -  History of hospitalization for asthma within 2 months or treatment for acute asthma in
             an ED within 2 weeks of study entry

          -  Past or current use of disallowed medications

          -  Participation in an investigational study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Nowak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital Emergency Department</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <results_first_submitted>February 17, 2010</results_first_submitted>
  <results_first_submitted_qc>May 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2010</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Richard M Nowak</investigator_full_name>
    <investigator_title>Sr. Staff Physician DEM</investigator_title>
  </responsible_party>
  <keyword>Acute asthma</keyword>
  <keyword>Arformoterol</keyword>
  <keyword>Long acting beta agonists</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was open for enrollment from 1/8/09 until 11/19/09. Location was Henry Ford Hospital Emergency Department</recruitment_details>
      <pre_assignment_details>Only 2 patients were enrolled in this trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arformoterol 1 Dose, Placebo 2 Doses</title>
        </group>
        <group group_id="P2">
          <title>Arformoterol 3 Doses</title>
        </group>
        <group group_id="P3">
          <title>Levalbuterol 3 Doses</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arformoterol 1 Dose, Placebo 2 Doses</title>
        </group>
        <group group_id="B2">
          <title>Arformoterol 3 Doses</title>
        </group>
        <group group_id="B3">
          <title>Levalbuterol 3 Doses</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Age group 18-65 years of age</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Most Effective Dose of Inhalation Arformoterol for Treating Acute Bronchospasm in Asthmatics by Evaluating the Averaged Mean Percent Change From Baseline % Predicted FEV1 After 3 Doses of Study Medication in Each of the 3 Groups</title>
        <time_frame>1 hour</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Treated With Arformoteral in Acute Asthma Exacerbation as a Measure of Safety and Tolerability.</title>
        <time_frame>5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Averaged Mean Percent Change From Baseline FEV1 and PEFR (Percent Predicted and Absolute) After the 3 Doses of Study Drug</title>
        <time_frame>1 hour</time_frame>
        <population>As the study was terminated with 2 subjects enrolled, those 2 subjects were used for the limited statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arformoterol 1 Dose, Placebo 2 Doses</title>
          </group>
          <group group_id="O2">
            <title>Arformoterol 3 Doses</title>
          </group>
          <group group_id="O3">
            <title>Levalbuterol 3 Doses</title>
          </group>
        </group_list>
        <measure>
          <title>The Averaged Mean Percent Change From Baseline FEV1 and PEFR (Percent Predicted and Absolute) After the 3 Doses of Study Drug</title>
          <population>As the study was terminated with 2 subjects enrolled, those 2 subjects were used for the limited statistical analysis.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</title>
        <time_frame>1 hour</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</title>
        <time_frame>1 hour</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Peak Change (Liters) and Peak Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug</title>
        <time_frame>1 hour</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Onset of a 15% Improvement in FEV1 for Each Dose (Individual and Cumulative) and Total Dose of Study Medication to Reach This</title>
        <time_frame>5 hour</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time Required to Achieve a FEV1 and PEFR &gt; 60% Predicted for Each Dose (Individual and Cumulative)</title>
        <time_frame>5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Responders (Defined as Those Discharged Following Treatment Who Did Not Require Additional Therapy in the ED)</title>
        <description>The 2 subjects enrolled were both discharged home after study protocol completion, with no further treatment required in the ED setting.</description>
        <time_frame>5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients in Each Group Requiring Additional Therapies After the First Hour of Study Drug Treatments</title>
        <description>2 subjects were enrolled. Neither required additional asthma treatment after the 1st hour of study drug teatments.</description>
        <time_frame>5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All of the Primary and Secondary Endpoints Partitioned by the Presenting PFT in Quartiles and the Presenting S Albuterol Levels in Quartiles</title>
        <time_frame>5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Arformoterol in This Clinical Setting</title>
        <time_frame>5 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arformoterol 1 Dose, Placebo 2 Doses</title>
        </group>
        <group group_id="E2">
          <title>Arformoterol 3 Doses</title>
        </group>
        <group group_id="E3">
          <title>Levalbuterol 3 Doses</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard M Nowak MD</name_or_title>
      <organization>Henry Ford Health System, Detroit, Michigan</organization>
      <phone>313 881 0023</phone>
      <email>rnowak1@hfhs.staff</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

